TheEdgeResearch
Home / Stocks / CLVSF

CellaVision AB (publ) (CLVSF)

OTC Healthcare Medical - Devices
$14.00 ▲ +0.00%
Market Cap
$333.9M
Sector
Healthcare
Industry
Medical - Devices
Beta
0.97
52-Wk Range
13.49-19.2796
CEO
Steve Ferguson
Country
SE
Currency
USD

CellaVision AB (publ) operates in the Medical - Devices industry of the Healthcare sector, headquartered in Lund, SN, SE. The stock last traded at $14.00, up 0.00% on the session, giving a market capitalisation of $333.9M. On trailing twelve-month figures it carries a trailing P/E of 28.17, a net margin of 17.5%. Its beta of 0.97 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
28.17
Price / Sales
4.92
Price / Book
4.10
EV / EBITDA
16.88
Gross margin
68.7%
Operating margin
22.2%
Net margin
17.5%
Return on equity
Debt / equity
0.06
Current ratio
3.31
Dividend yield
1.8%
Payout ratio
50.8%
Company profile
Exchange
Other OTC
Employees
251
IPO date
2013-08-20
Headquarters
Lund, SN, SE
About CellaVision AB (publ)

CellaVision AB (publ), a company established in Lund, Sweden, in 1994, specializes in the development and distribution of digital analytical solutions for blood and body fluid samples. Their offerings cater to the healthcare services sector, with a significant global presence spanning Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific region. The company's product portfolio includes advanced hardware such as the CellaVision DM1200 and CellaVision DM9600, which are designed to automatically capture digital images from blood smears and various body fluid preparations, alongside the CellaVision DC-1 analyzer. Complementing their instrumentation is a suite of specialized software applications. For instance, the CellaVision Peripheral Blood Application streamlines and standardizes the morphological examination of peripheral blood smears for laboratory professionals. Similarly, the CellaVision Advanced RBC Application facilitates a comprehensive evaluation of red blood cell morphology, while the CellaVision Body Fluid Application offers automated and standardized analysis for body fluid preparations. To enhance collaboration and flexibility, the CellaVision Remote Review Software eliminates geographical barriers in the smear review process. Further enriching their ecosystem are tools such as the CellaVision Server Software, which unifies workflows across single or multiple testing sites, and the CellaVision Dashboard, providing instant insights into analyzer and reviewer performance metrics. For staff development, the cloud-based CellaVision Proficiency Software aids laboratory managers in assessing and enhancing team competency in cell morphology. Educational resources include CellaVision CellAtlas, combining mini-lectures with an extensive cell image database. Finally, CellaVision VET extends their digital microscopy solutions to the field of veterinary hematology. Their clientele primarily consists of hospital and commercial diagnostic laboratories.

Comparable companies

CellaVision AB (publ) is most often compared with the following Healthcare names:

AVNBFBJTRFBOIRFCALZFFDMDFGSGTFJNDOFLBLTFMNFSFXVIPF
More research on CLVSF
CLVSF technical analysis CLVSF TheEdge Score Compare against peers
Open full interactive analysis & DCF →